Effect of colestilan on serum phosphorus in dialysis patients: A meta-analysis of the literature.
OBJECTIVE
To evaluate the efficacy and safety of colestilan as a phosphorus binder in dialysis patients, we performed a meta-analysis of randomized controlled trials.


METHODS
We retrieved studies that compared colestilan with placebo in the treatment of dialysis patients from Medline, EMBASE, the Cochrane Library and conference proceedings.


RESULTS
Four studies were included. The treatment durations ranged from 2 to 12 weeks, median 7.5 weeks. Compared with placebo group, colestilan significantly decreased serum phosphorus (WMD, -0.22 mmol/L; 95% CI, -0.33 to -0.12, P < 0.0001), calcium phosphorus product (WMD, -0.70 mmol(2) /L(2) ; 95% CI, -1.06 to -0.35, P = 0.0001), intact PTH (WMD, -5.37 pmol/L; 95% CI, -8.38 to -2.36, P = 0.0005) and LDL cholesterol (WMD, -0.78 mmol/L; 95% CI, -0.85 to -0.71, P < 0.00001). There was no significant difference in serum calcium between the two groups. Colestilan therapy increased gastrointestinal complaints significantly (OR = 4.07, 95% CI: 3.06-6.53, P < 0.00001). Sensitivity analysis was performed by excluding studies with Jadad score of three or 3 g/day colestilan, the results did not change.


CONCLUSIONS
Short-term administration of colestilan is effective for the treatment of hyperphosphataemia in dialysis patients. Long-term effectiveness and safety needs to be evaluated.
Division of Nephrology, Huashan Hospital, Shanghai, China.|Huashan Hospital North, Shanghai Medical College, Fudan University, Shanghai, China.
Qian
http://orcid.org/0000-0001-5715-4877
Q
Zhang
Department of Respiratory Medicine, Shanghai 10th People's Hospital Affiliated to Tongji University, Shanghai, China.
Ming
M
Li
Division of Nephrology, Huashan Hospital, Shanghai, China.
Jing
J
Chen
D001647:Bile Acids and Salts / Q000009:adverse effects / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D002614:Chelating Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016009:Chi-Square Distribution; D006801:Humans; D054559:Hyperphosphatemia / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D016017:Odds Ratio; D010758:Phosphorus / Q000097:blood*; D016032:Randomized Controlled Trials as Topic; D006435:Renal Dialysis / Q000009:adverse effects*; D013997:Time Factors; D016896:Treatment Outcome
D001647:Bile Acids and Salts; D015415:Biomarkers; D002614:Chelating Agents; D010758:Phosphorus; C106574:cholebine
colestilan,·haemodialysis; hyperphosphataemia; meta-analysis